Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × guadecitabine × 1 year × Clear all
NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
28 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡